相关实验视频
Updated: Jun 20, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.3K
恩帕格利弗洛辛:在-葡萄糖共载体-2 抑制剂中,它是首要的?
Giuseppe Biondi-Zoccai1,2, Giacomo Frati1,3, Mariangela Peruzzi2,4
1Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy.
Journal of cardiovascular pharmacology
|July 19, 2024
概括
/葡萄糖共运输体-2 (SGLT2) 抑制剂为各种患者提供显著的心血管益处. 最近关于empagliflozin在急性心肌梗塞中的研究表明,尽管复杂,但对心力衰竭的预防有希望的结果.
科学领域:
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- /葡萄糖共运输体-2 (SGLT2) 抑制剂是抗糖尿病药物的一类.
- 这些药物证明了除了血糖控制之外的显著心血管益处.
- 无论糖尿病状况如何,在心力衰竭和肥胖症中都观察到益处.
研究的目的:
- 审查SGLT2抑制剂的类特征.
- 讨论它们在心血管医学中的不断扩大的作用.
- 分析对empagliflozin在急性心肌梗塞中的有效性和最新数据的比较.
主要方法:
- 文献综述和对SGLT2抑制剂现有研究的综合.
- 专注于心血管结果,特别是心力衰竭.
- 对EMPA-MI对empagliflozin的试验数据的分析.
主要成果:
- SGLT2 抑制剂对心血管疾病的预防和治疗具有有利的类效应.
- 最近对empagliflozin在急性心肌梗塞的试验产生了关于心力衰竭的复杂发现.
- 个别的SGLT2抑制剂可以提供个性化的护理和副作用管理.
结论:
- SGLT2 抑制剂代表了心血管药物治疗的重大进展.
- 类效应是强大的,个体药剂的差异指导个性化治疗.
- 需要进一步的研究来充分阐明empagliflozin在心肌梗塞后的作用.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
186
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
186
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Glucagon-like Receptor Agonists
312
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
312
Secondary Active Transport
119.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
119.1K
Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168

